Full Press Release Details
Change of Director s Interest Notice
Change of Director s Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX s property and may be made public.
Introduced 30/9/2001.
| Name of Entity: | PRIMA BIOMED LIMITED | (ASX:PRR) | ||
| ACN: | 90 009 237 889 |
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the
purposes of section 205G of the Corporations Act.
| Name of Director: | Ms Lucy Turnbull | |
| Date of Last Notice: | 19.06.2013 |
Part 1 - Change of director s relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of notifiable interest of a director should
be disclosed in this part.
| Direct or indirect interest | Indirect | |||||||||
| Nature of indirect interest | Director related entities | |||||||||
| (including registered holder) | Turnbull & Partners Pty Ltd | |||||||||
| Note: Provide details of the circumstances giving rise to the relevant interest. | ||||||||||
| Date of change | 18 June 2013 | |||||||||
| No. of securities held prior to change | Shares | Options | ||||||||
| Direct | 17,034,576 | 14,258,644 | ||||||||
| Indirect | 725,000 | 68,750 | ||||||||
| Total | 17,759,576 | 14,327,394 | ||||||||
| Class | Listed options | |||||||||
| Number acquired | Shares | Options | ||||||||
| Direct | ||||||||||
| Indirect | 112,500 | |||||||||
| Total | 112,500 |
Change of Director s Interest Notice
| Number disposed | Shares | Options | ||||||||
| Direct | ||||||||||
| Indirect | ||||||||||
| Total | ||||||||||
| Value/Consideration | AUD 2,250 | |||||||||
| Note: If consideration is non-cash, provide details and estimated valuation | ||||||||||
| No. of securities held after change | Shares | Options | ||||||||
| Direct | 17,034,576 | 14,258,644 | ||||||||
| Indirect | 725,000 | 181,250 | ||||||||
| Total | 17,759,576 | 14,439,894 | ||||||||
| Nature of change | ||||||||||
| Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back | Acquiring 112,500 listed options at AUD 0.02 each |
Part 2 - Change of director s interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of notifiable interest of a director should be disclosed in this part.
| Detail of contract | N/A | |
| Nature of interest | ||
| Name of registered holder | ||
| (if issued securities) | ||
| Date of change | ||
| No. and class of securities to which interest related prior to change | ||
| Note: Details are only required for a contract in relation to which the interest has changed | ||
| Interest acquired | ||
| Interest disposed | ||
| Value/Consideration | ||
| Note: If consideration is non-cash, provide details and an estimated valuation | ||
| Interest after change |
Part 3 - +Closed Period
| Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? | No | |
| If so, was prior written clearance provided to allow the trade to proceed during this period? | ||
| If prior written clearance was provided on what date was this provided? |
Change of Director s Interest Notice
Prima BioMed Limited
LATE LODGEMENT OF CHANGE IN DIRECTOR S INTEREST NOTICE
Having regard to ASX Listing Rules 3.19A and 3.19B and Guidance Note 22:
Director Disclosure of Interests and Transactions in Securities - Obligations of Listed Entities , the Company makes the following submissions in relation to the late lodgement of the Change of Director s Interest Notice:
The Appendix 3Y was not lodged within 5 business days after the change of the Director s interest (i.e. by 25 June 2013) due to the delay in the director s brokerage custodian platform
informing the director of the allocation of an additional AUD 2,250 worth of PRRO options indirectly held by the Director. This allocation of PRRO options arose from the director s participation in the Company s Options Entitlement Offer.
The majority of the Director s PRRO allocation (i.e. AUD 86,547.88 worth) was previously disclosed in the Appendix 3Y, released on 19 June 2013.
The Company confirms that it is aware of and understands its obligations under the Corporations Act 2001 (Cth) and ASX Listing Rules, in particular the obligations under Listing Rules 3.19A and 3.19B.
The Company considers that it has the necessary education, reporting and notification policies in place to ensure compliance
with the disclosure obligations under Listing Rule 3.19A. The Company ensures that all Directors are notified of their obligations to inform the Company of any changes in their relevant interests at the time of their appointment.
The Directors are aware of their obligations to inform the Company Secretary of all information necessary for the Company to comply with its obligations
under listing rule 3.19A.
The Company considers its current arrangements are adequate for ensuring timely notification. However, the Company will continue to review and update its
policies as and when appropriate.